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Introduction
Systemic lupus erythematosus (SLE) is a multisystem
disease of autoimmune etiology, which carries a high
morbidity and mortality.
Objectives
To describe clinical and immunoserological features at
the time of diagnosis within a cohort of pediatric
patients attending the service of rheumatology of a
Colombian pediatric hospital.
Methods
Cross-sectional study. 89 patients with diagnosis SLE
(1986 ACR criteria) from a rheumatology center at a
pediatric hospital were evaluated. Medical records were
reviewed registering the following variables: sex, mean
age, score SLEDAI, organ involvement, current pharma-
cological treatment and autoimmune profile. Descriptive
analysis was done for qualitative and categorical vari-
ables (percentages and averages) using STATA11.
Results
76 patients (85.4%) were female and 13 (14.6%) were men.
Mean age 11.3 y/o (min 2 max 16). Median score SLEDAI
at onset was 23 (min 4 max 61). Organ involvement: Renal
75 patients (84,3%), hematologic 75 (84,3%), skin 60
(67,4%), neurolupus 26 (29,9%), serositis 17 (19,1%), arthri-
tis 50 (56,18%), Raynaud 8 (10,1%), photosensitivity 34
(52,3%). Current pharmacological treatment: antimalarials
80 (93%), Azathioprine 57 (64%), Cyclophosphamide 33
(38,8%), Mycophenolate Mofetil 8 (9,6%), Rituximab
4 (4,5%), Cyclosporine 1 (1,1%). Autoimune profile:
Antinuclear antibodies (ANAs) reactivity 74 (88,1%),
Anti-DNA antibodies 56 (66,7%), Antiphospholipid anti-
bodies (aPL) 25 (38,1%).
Conclusion
The demographic characteristics and laboratory tests of
this cohort are according to previously reported in
worldwide and latin American literature. The score
SLEDAI at the diagnosis was found in median activity.
The most common medications prescribed were antima-
larials followed by azathioprine and cyclophosphamide.
Disclosure of interest
None declared.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P268
Cite this article as: Diaz Maldonado et al.: PReS-FINAL-2278: Description
of a Colombian cohort of patients with childhood systemic
lupus erytematosus. Pediatric Rheumatology 2013 11(Suppl 2):P268.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Reumatologia Pediatrica, Hospital de La Misericordia, Bogota, Colombia
Diaz Maldonado et al. Pediatric Rheumatology 2013, 11(Suppl 2):P268
http://www.ped-rheum.com/content/11/S2/P268
© 2013 Diaz Maldonado et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
